Recombinant Viral HCV E2 Protein, CF

When Recombinant Human CD81 LEL Fc Chimera (Catalog # 9144-CD) is coated onto a microplate at 2 μg/ml, Recombinant Viral HCV E2 (Catalog # 9146-HC) bindswith an ED50 of 0.2-1.2 µg/mL.

• Reactivity: V
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Viral HCV E2 Protein, CF Summary

• Additional Information: Hepatitis C Virus 1b Envelope Glycoprotein E2
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CD81 LEL Fc Chimera (Catalog # 9144-CD) is coated onto a microplate at 2 μg/mL, Recombinant Viral HCV E2 binds with an ED₅₀ of 0.2-1.2 µg/mL.
• Source: Human embryonic kidney cell, HEK293-derived viral HCV E2 protein
  Glu384-Glu661, with a C-terminal 6-His tag
• Accession #: NP_671491
• N-terminal Sequence: Glu384
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 31 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 63-74 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Viral HCV E2 Protein, CF

• HCV E2
• HCV-E2
• hcvGP-E2
• Hep C E2

Background

Glycoprotein E2 is an approximately 60 kDa viral envelope protein encoded by the hepatitis C virus (HCV) genome (1-3). HCV infection is closely associated with the development of hepatocellular carcinoma and cirrhosis of the liver. E2 is a transmembrane molecule expressed as a noncovalent dimer with the E1 glycoprotein (4). It binds to CD81 and CD36/SR-BI on hepatocytes, and glycosylation of E2 is important for this interaction (4-8). The virus also requires target cell expression of the tight junction proteins Claudin-1 and Occludin for infectivity (7, 9, 10). CD81 and Occludin are responsible for the human host cell specificity of HCV (10). E2 binding to CD81 on NK cells inhibits cytokine production and cytolytic activity (11, 12). In contrast, E2 binding to CD81 on T cells provides a costimulatory signal (11, 12). On plasmacytoid dendritic cells, E2 binds to CD81 as well as BDCA-2 and DCIR, resulting in inhibition of IFN-alpha production and cell maturation (13, 14).

1. Khan, A.G. et al. (2015) Curr. Opin. Virol. 12:53.
2. Zona, L. et al. (2014) Viruses 6:875.
3. Grakoui, A. et al. (1993) J. Virol. 67:1385.
4. Op De Beeck, A. et al. (2004) J. Virol. 78:2994.
5. Pileri, P. et al. (1998) Science 282:938.
6. Scarselli, E. et al. (2002) EMBO J. 21:5017.
7. Harris, H.J. et al. (2010) J. Biol. Chem. 285:21092.
8. Falkowska, E. et al. (2007) J. Virol. 81:8072.
9. Evans, M.J. et al. (2007) Nature 446:801.
10. Ploss, A. et al. (2009) Nature 457:882.
11. Crotta, S. et al. (2002) J. Exp. Med. 195:35.
12. Tseng, C.-T. and G.R. Klimpel (2002) J. Exp. Med. 195:43.
13. Tu, Z. et al. (2013) Cell. Immunol. 284:98.
14. Florentin, J. et al. (2012) Blood 120:4544.

Bioinformatics

• Uniprot:
  • NP_671491()